Phase II Trial of Bortezomib Alone or in Combination with Irinotecan in Patients with Adenocarcinoma of the Gastroesophageal Junction or Stomach

PURPOSE: To determine the effectiveness of bortezomib plus irinotecan and bortezomib alone in patients with advanced gastroesophageal junction (GEJ) and gastric adenocarcinoma. We also sought to explore the effect of these therapeutics on tumor and normal gene expression in vivo. METHODS: Forty-one...

Deskribapen osoa

Gorde:
Xehetasun bibliografikoak
Egile Nagusiak: Ocean, Allyson J., Christos, Paul, Sparano, Joseph A., Shah, Manish A., Yantiss, Rhonda K., Cheng, Jonathan, Lin, Juan, Papetti, Michael, Matulich, Dan, Schnoll-Sussman, Felice, Besanceney-Webler, Christen, Xiang, Jenny, Ward, Maureen, Dilts, Kaili Temple, Keresztes, Roger, Holloway, Shannon, Chen, Eric X., Wright, John J., Lane, Maureen E.
Formatua: Artigo
Hizkuntza:Inglês
Argitaratua: 2014
Gaiak:
Article
Sarrera elektronikoa:https://ncbi.nlm.nih.gov/pmc/articles/PMC4047141/
https://ncbi.nlm.nih.gov/pubmed/24526575
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1007/s10637-014-0070-0
Etiketak: Etiketa erantsi
Etiketarik gabe, Izan zaitez lehena erregistro honi etiketa jartzen!

Antzeko izenburuak